Paper41345954
A novel immunocytokine promotes T cell- and cytokine-induced killer cell-mediated antitumor immunity via a non-MHC-restricted mechanism in glioblastoma.
Zhang X and 13 others. J Transl Med, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. A novel immunocytokine promotes T cell- and cytokine-induced killer cell-mediated antitumor immunity via a non-MHC-restricted mechanism in glioblastoma. Papers, record 41345954. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41345954
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A novel immunocytokine promotes T cell- and cytokine-induced killer cell-mediated antitumor immunity via a non-MHC-restricted mechanism in glioblastoma.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glioblastoma | Major topic |
| T-Lymphocytes | Major topic |
| Cytokines | Major topic |
| Brain Neoplasms | Major topic |
| Killer Cells, Natural | Major topic |
| Humans | |
| Animals | |
| Cell Line, Tumor | |
| Interleukin-15 | |
| Tumor Microenvironment | |
| Recombinant Fusion Proteins | |
| Cytotoxicity, Immunologic |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82473334 | National Natural Science Foundation of China | PubMed | ||
| 32471551 | National Natural Science Foundation of China | PubMed | ||
| 2022CJE09013 | Major Scientific and Technological Achievements Transformation Project of Ningxia Hui Autonomous Region | PubMed | ||
| 24CXTD15 | Project Fund of Sichuan Provincial Healthommission | PubMed | ||
| 2023ZYDF097 | Mianyang Science and Technology Bureau | PubMed | ||
| NHC Key Laboratory of Nuclear Technology Medical Transformation(MIANYANG CENTRAL HOSPITAL) | NHC Key Laboratory of Nuclear Technology Medical Transformation(MIANYANG CENTRAL HOSPITAL) | PubMed |
Source PubMed
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35876221 | Multivalent, Bispecific αB7-H3-αCD3 Chemically Self-Assembled Nanorings Direct Potent T Cell Responses against Medulloblastoma. | ACS Nano | 2022 | https://conductscience.org/library/papers/35876221 | PubMed |
| 2 | 32296583 | Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment via the HMGB1/RAGE/IL-8 axis. | Cancer Biol Med | 2020 | https://conductscience.org/library/papers/32296583 | PubMed |
| 3 | 37097811 | Engineering MMP-2 Activated Nanoparticles Carrying B7-H3 Bispecific Antibodies for Ferroptosis-Enhanced Glioblastoma Immunotherapy. | ACS Nano | 2023 | https://conductscience.org/library/papers/37097811 | PubMed |
| 4 | 28003994 | Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? | Front Oncol | 2016 | https://conductscience.org/library/papers/28003994 | PubMed |
| 5 | 38167707 | IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity. | Nat Commun | 2024 | https://conductscience.org/library/papers/38167707 | PubMed |
| 6 | 36371226 | Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies. | J Hematol Oncol | 2022 | https://conductscience.org/library/papers/36371226 | PubMed |
| 7 | 37409128 | IL-15 promotes self-renewal of progenitor exhausted CD8 T cells during persistent antigenic stimulation. | Front Immunol | 2023 | https://conductscience.org/library/papers/37409128 | PubMed |
| 8 | 28888485 | Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent. | Cytokine Growth Factor Rev | 2017 | https://conductscience.org/library/papers/28888485 | PubMed |
| 9 | 36056553 | CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. | Mol Ther | 2023 | https://conductscience.org/library/papers/36056553 | PubMed |
| 10 | 38132354 | Immune Escape in Glioblastoma: Mechanisms of Action and Implications for Immune Checkpoint Inhibitors and CAR T-Cell Therapy. | Biology (Basel) | 2023 | https://conductscience.org/library/papers/38132354 | PubMed |
| 11 | 27302161 | Checkpoint Antibodies but not T Cell-Recruiting Diabodies Effectively Synergize with TIL-Inducing γ-Irradiation. | Cancer Res | 2016 | https://conductscience.org/library/papers/27302161 | PubMed |
| 12 | 24048123 | Innate and adaptive immune cells in the tumor microenvironment. | Nat Immunol | 2013 | https://conductscience.org/library/papers/24048123 | PubMed |
| 13 | 33763293 | A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy. | Oncoimmunology | 2021 | https://conductscience.org/library/papers/33763293 | PubMed |
| 14 | 38455459 | IL-15 in T-Cell Responses and Immunopathogenesis. | Immune Netw | 2024 | https://conductscience.org/library/papers/38455459 | PubMed |
| 15 | 26206773 | The CD40/CD40L axis in glioma progression and therapy. | Neuro Oncol | 2015 | https://conductscience.org/library/papers/26206773 | PubMed |
| 16 | 37564196 | B7-H3 in Brain Malignancies: Immunology and Immunotherapy. | Int J Biol Sci | 2023 | https://conductscience.org/library/papers/37564196 | PubMed |
| 17 | 40794737 | A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors. | Cancer Res Commun | 2025 | https://conductscience.org/library/papers/40794737 | PubMed |
| 18 | 35570396 | Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. | Mol Ther | 2022 | https://conductscience.org/library/papers/35570396 | PubMed |
| 19 | 31332324 | CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. | Nat Biotechnol | 2019 | https://conductscience.org/library/papers/31332324 | PubMed |
| 20 | 33589826 | Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity. | Nat Protoc | 2021 | https://conductscience.org/library/papers/33589826 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42891082 | Immunocytokines in cancer: a safety perspective. | Front Immunol | 2026 | https://conductscience.org/library/papers/42891082 | PubMed |
| 42545507 | Improving T-cell engager efficacy in glioblastoma with multi-antigen targeting and novel delivery approaches. | Acta Neuropathol | 2026 | https://conductscience.org/library/papers/42545507 | PubMed |
| 42396877 | Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment. | Immunol Cell Biol | 2026 | https://conductscience.org/library/papers/42396877 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41345954
GET https://conductscience.org/api/papers/v1/41345954/references?page=2